10 likes | 99 Views
RUTHERFORD-2: mean change in LDL-c levels with evolocumab or placebo biweekly or monthly in HeFH. Change from baseline in LDL cholesterol (%). Raal et al., The Lancet Oct 2014.
E N D
RUTHERFORD-2: mean change in LDL-c levels with evolocumab or placebo biweekly or monthly in HeFH Change from baseline in LDL cholesterol (%) Raal et al., The Lancet Oct 2014